|Videos|May 22, 2021
Neoadjuvant Therapy for HR+ Breast Cancer
Author(s)Kevin Kalinsky, MD, MS
Dr Kevin Kalinsky describes when and for whom neoadjuvant therapy may be appropriate for the management of HR-positive breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
In the phase 2 IBEX trial, iberdomide plus subcutaneous daratumumab post-transplant maintenance improved MRD status in patients with multiple myeloma.
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
Longer follow-up is needed for the phase 3 MIDAS trial to determine the impact of MRD conversion on progression-free survival and overall survival.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Acting on a HER2 Result and Navigating Access to Therapy
3
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
4
FDA Clears TriNav Advance for Expanded Liver Embolization Access
5